| 原著 |
|
|
|
|
| 一例肿瘤合并2019冠状病毒病(COVID-19)患者的治疗决策分析 |
叶子奇( ),洪昀,吴秀华,洪东升,张燕芳,董曦浩,饶跃峰*(),卢晓阳*() |
| 浙江大学医学院附属第一医院药学部, 浙江 杭州 310003 |
|
| Management of a colon cancer patient complicated with COVID-19 |
| YE Ziqi(),HONG Yun,WU Xiuhua,HONG Dongsheng,ZHANG Yanfang,DONG Xihao,RAO Yuefeng*(),LU Xiaoyang*() |
| Department of Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China |
引用本文:
叶子奇,洪昀,吴秀华,洪东升,张燕芳,董曦浩,饶跃峰,卢晓阳. 一例肿瘤合并2019冠状病毒病(COVID-19)患者的治疗决策分析[J]. 浙江大学学报（医学版）, 2020, 49(2): 245-248.
YE Ziqi,HONG Yun,WU Xiuhua,HONG Dongsheng,ZHANG Yanfang,DONG Xihao,RAO Yuefeng,LU Xiaoyang. Management of a colon cancer patient complicated with COVID-19. J Zhejiang Univ (Med Sci), 2020, 49(2): 245-248.
链接本文:
http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.03.12
或
http://www.zjujournals.com/med/CN/Y2020/V49/I2/245
|
| 1 |
KAMBOJ M , SEPKOWITZ K A . Nosocomial infections in patients with cancer[J]. Lancet Oncol, 2009, 10 (6): 589- 597
doi: 10.1016/S1470-2045(09)70069-5
|
| 2 |
LI J Y , DUAN X F , WANG L P et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer[J]. J Immunol Res, 2014, 2014 286170
doi: 10.1155/2014/286170
|
| 3 |
LONGBOTTOM E R , TORRANCE H D , OWEN H C et al. Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways[J]. Ann Surg, 2016, 264 (2): 370- 377
doi: 10.1097/SLA.0000000000001484
|
| 4 |
SICA A , MASSAROTTI M . Myeloid suppressor cells in cancer and autoimmunity[J]. J Autoimmun, 2017, 85 117- 125
doi: 10.1016/j.jaut.2017.07.010
|
| 5 |
LIANG W , GUAN W , CHEN R et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China[J]. Lancet Oncol, 2020, 21 (3): 335- 337
doi: 10.1016/S1470-2045(20)30096-6
|
| 6 |
中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第七版)[A/OL].国卫办医函〔2020〕184号.(2020-03-03)[2020-03-10].http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
General Office of National Health Commission of the People's Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment of novel coronavirus pneumonia (trial version 7)[A/OL]. No.184〔2020〕 of the General Office of the National Health Commission. (2020-03-03)[2020-03-10]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml. (in Chinese)
|
| 7 |
HUANG C , WANG Y , LI X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395 (10223): 497- 506
doi: 10.1016/S0140-6736(20)30183-5
|
| 8 |
WANG D, HU B, HU C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J/OL]. JAMA, 2020: e201585. DOI: 10.1001/jama.2020.1585.
|
| 9 |
HEINEMANN V , VON WEIKERSTHAL L F , DECKER T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer(FIRE-3): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2014, 15 (10): 1065- 1075
doi: 10.1016/S1470-2045(14)70330-4
|
| 10 |
黄耿文 . 新型冠状病毒肺炎疫情下实施普通外科手术的思考和建议[J]. 中华普通外科杂志, 2020, 29 (2): 127- 130
HUANG Gengwen . Thoughts and advices on performing procedures in general surgery during the outbreak of novel coronavirus pneumonia[J]. Chinese Journal of General Surgery, 2020, 29 (2): 127- 130
doi: 10.7659/j.issn.1005-6947.2020.02.001
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
